NasdaqGM - Nasdaq Real Time Price USD

NeuroPace, Inc. (NPCE)

Compare
7.39 +0.57 (+8.36%)
At close: September 19 at 4:00 PM EDT
7.11 -0.28 (-3.79%)
After hours: September 19 at 5:09 PM EDT
Loading Chart for NPCE
DELL
  • Previous Close 6.82
  • Open 7.10
  • Bid 5.19 x 200
  • Ask 8.79 x 200
  • Day's Range 6.83 - 7.39
  • 52 Week Range 5.75 - 18.15
  • Volume 34,685
  • Avg. Volume 93,107
  • Market Cap (intraday) 215.766M
  • Beta (5Y Monthly) 1.80
  • PE Ratio (TTM) --
  • EPS (TTM) -1.08
  • Earnings Date Nov 4, 2024 - Nov 8, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 15.50

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

www.neuropace.com

179

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NPCE

View More

Research Reports: NPCE

View More

Performance Overview: NPCE

Trailing total returns as of 9/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NPCE
28.32%
S&P 500
19.79%

1-Year Return

NPCE
8.54%
S&P 500
28.29%

3-Year Return

NPCE
57.58%
S&P 500
28.89%

5-Year Return

NPCE
68.22%
S&P 500
38.18%

Compare To: NPCE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NPCE

View More

Valuation Measures

Annual
As of 9/19/2024
  • Market Cap

    215.77M

  • Enterprise Value

    233.89M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.83

  • Price/Book (mrq)

    21.83

  • Enterprise Value/Revenue

    3.26

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -41.63%

  • Return on Assets (ttm)

    -15.75%

  • Return on Equity (ttm)

    -192.19%

  • Revenue (ttm)

    71.82M

  • Net Income Avi to Common (ttm)

    -29.9M

  • Diluted EPS (ttm)

    -1.08

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    55.54M

  • Total Debt/Equity (mrq)

    745.17%

  • Levered Free Cash Flow (ttm)

    -10.3M

Research Analysis: NPCE

View More

Company Insights: NPCE

People Also Watch